<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03169738</url>
  </required_header>
  <id_info>
    <org_study_id>QUILT-3.044</org_study_id>
    <nct_id>NCT03169738</nct_id>
  </id_info>
  <brief_title>QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors</brief_title>
  <official_title>NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With Programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunityBio, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination&#xD;
      therapy in subjects with NSCLC who have progressed on or after treatment with PD-1/PD-L1&#xD;
      inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will be administered in 2 phases, an induction and a maintenance phase, as&#xD;
      described below. Subjects will continue induction treatment for up to 1 year. Treatment in&#xD;
      the study will be discontinued if the subject experiences progressive disease (PD) or&#xD;
      unacceptable toxicity (not correctable with dose reduction), withdraws consent, or if the&#xD;
      Investigator feels it is no longer in the subject's best interest to continue treatment.&#xD;
      Those who have a complete response (CR) in the induction phase will enter the maintenance&#xD;
      phase of the study. Subjects may remain on the maintenance phase of the study for up to 1&#xD;
      year. Treatment will continue in the maintenance phase until the subject experiences PD or&#xD;
      unacceptable toxicity (not correctable with dose reduction), withdraws consent, or if the&#xD;
      Investigator feels it is no longer in the subject's best interest to continue treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Trial not initiated&#xD;
  </why_stopped>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 1b primary endpoint (safety)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 primary endpoint (ORR by RECIST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR by Immune-related response criteria (irRC )</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 2 primary endpoint (ORR by irRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR by RECIST Version 1.1</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 1b secondary endpoint (ORR by RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR by irRC</measure>
    <time_frame>1 year</time_frame>
    <description>Phase 1b secondary endpoint (ORR by irRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) by RECIST Version 1.1</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 1b and 2 secondary endpoint (PFS by RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS by irRC</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 1b and 2 secondary endpoint (PFS by irRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS): time from the date of first treatment to the date of death (any cause)</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 1b and 2 secondary endpoint (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DR): time from the date of first response (partial response (PR) or complete response (CR)) to the date of disease progression or death (any cause) whichever occurs first</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 1b and 2 secondary endpoint (DR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR): confirmed complete response, partial response, or stable disease lasting for at least 2 months</measure>
    <time_frame>2 months</time_frame>
    <description>Phase 1b and 2 secondary endpoint (DCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) by patient-reported outcome using the Functional Assessment of Cancer Therapy-Lung (FACT-L)</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 1b and 2 secondary endpoint (QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03</measure>
    <time_frame>2 years</time_frame>
    <description>Phase 2 secondary endpoint (AEs)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-fluorouracil, fulvestrant, leucovorin, nab paclitaxel, nivolumab, lovaza, oxaliplatin, stereotactic body radiation therapy, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, and haNK.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>avelumab</intervention_name>
    <description>Fully human anti-PD-L1 IgG1 lambda monoclonal antibody</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>(SP-4-2)-diamminedichloroplatinum(II)</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil (5-FU)</intervention_name>
    <description>5-fluoro-2,4 (1H,3H)-pyrimidinedione</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin</intervention_name>
    <description>Calcium N-[p-[[[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab paclitaxel</intervention_name>
    <description>5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Human anti-PD-1 IgG4 kappa monoclonal antibody</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>Omega-3-acid ethyl esters</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>(SRBT)</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL15N72D:IL-15RαSu/IgG1 Fc complex]</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-011</intervention_name>
    <description>adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-021</intervention_name>
    <description>Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-051</intervention_name>
    <description>Ad5 [E1-, E2b-]-Brachyury vaccine</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ETBX-061</intervention_name>
    <description>Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-4000</intervention_name>
    <description>Ras yeast vaccine</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6207</intervention_name>
    <description>CEA yeast vaccine</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GI-6301</intervention_name>
    <description>Brachyury yeast vaccine</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haNK</intervention_name>
    <description>NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion</description>
    <arm_group_label>Nant NSCLC Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. Able to understand and provide a signed informed consent that fulfills the relevant&#xD;
             Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.&#xD;
&#xD;
          3. Histologically-confirmed NSCLC with progression on or after treatment with PD-1/PD-L1&#xD;
             inhibitors for their indicated usages.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          5. Have at least 1 measurable lesion of ≥ 1.5 cm.&#xD;
&#xD;
          6. Must have a recent tumor biopsy specimen obtained following the conclusion of the most&#xD;
             recent anti-cancer treatment. If an historic specimen is not available, the subject&#xD;
             must be willing to undergo a biopsy during the screening period.&#xD;
&#xD;
          7. Must be willing to provide blood samples and, if considered safe by the Investigator,&#xD;
             a tumor biopsy specimen at 8 weeks after the start of treatment.&#xD;
&#xD;
          8. Ability to attend required study visits and return for adequate follow-up, as required&#xD;
             by this protocol.&#xD;
&#xD;
          9. Agreement to practice effective contraception for female subjects of child-bearing&#xD;
             potential and non-sterile males. Female subjects of child-bearing potential must agree&#xD;
             to use effective contraception for up to 1 year after completion of therapy, and&#xD;
             non-sterile male subjects must agree to use a condom for up to 4 months after&#xD;
             treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of persistent grade 2 or higher (CTCAE Version 4.03) hematologic toxicity&#xD;
             resulting from previous therapy.&#xD;
&#xD;
          2. History of other active malignancies or brain metastasis except controlled basal cell&#xD;
             carcinoma; prior history of in situ cancer (eg, breast, melanoma, cervical); prior&#xD;
             history of prostate cancer that is not under active systemic treatment (except&#xD;
             hormonal therapy) and with undetectable prostate-specific antigen (PSA) (&lt; 0.2 ng/mL);&#xD;
             and bulky (≥ 1.5 cm) disease with metastasis in the central hilar area of the chest&#xD;
             and involving the pulmonary vasculature. Subjects with a history of another malignancy&#xD;
             must have &gt; 5 years without evidence of disease.&#xD;
&#xD;
          3. Serious uncontrolled concomitant disease that would contraindicate the use of the&#xD;
             investigational drug used in this study or that would put the subject at high risk for&#xD;
             treatment-related complications.&#xD;
&#xD;
          4. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's&#xD;
             disease, autoimmune disease associated with lymphoma).&#xD;
&#xD;
          5. History of organ transplant requiring immunosuppression.&#xD;
&#xD;
          6. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative&#xD;
             colitis).&#xD;
&#xD;
          7. Requires whole blood transfusion to meet eligibility criteria.&#xD;
&#xD;
          8. Inadequate organ function, evidenced by the following laboratory results:&#xD;
&#xD;
               1. White blood cell (WBC) count &lt; 3,500 cells/mm3.&#xD;
&#xD;
               2. Absolute neutrophil count &lt; 1,500 cells/mm3.&#xD;
&#xD;
               3. Platelet count &lt; 100,000 cells/mm3.&#xD;
&#xD;
               4. Hemoglobin &lt; 9 g/dL.&#xD;
&#xD;
               5. Total bilirubin greater than the upper limit of normal (ULN; unless the subject&#xD;
                  has documented Gilbert's syndrome).&#xD;
&#xD;
               6. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])&#xD;
                  &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver metastases).&#xD;
&#xD;
               7. Alkaline phosphatase (ALP) levels &gt; 2.5 × ULN (&gt; 5 × ULN in subjects with liver&#xD;
                  metastases, or &gt;10 × ULN in subjects with bone metastases).&#xD;
&#xD;
               8. Serum creatinine &gt; 2.0 mg/dL or 177 μmol/L.&#xD;
&#xD;
               9. International normalized ratio (INR) or activated partial thromboplastin time&#xD;
                  (aPTT) or partial thromboplastin time (PTT) &gt;1.5 × ULN (unless on therapeutic&#xD;
                  anti-coagulation).&#xD;
&#xD;
          9. Uncontrolled hypertension (systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg) or&#xD;
             clinically significant (ie, active) cardiovascular disease, cerebrovascular&#xD;
             accident/stroke, or myocardial infarction within 6 months prior to first study&#xD;
             medication; unstable angina; congestive heart failure of New York Heart Association&#xD;
             grade 2 or higher; or serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
         10. Dyspnea at rest due to complications of advanced malignancy or other disease requiring&#xD;
             continuous oxygen therapy.&#xD;
&#xD;
         11. Positive results of screening test for human immunodeficiency virus (HIV), hepatitis B&#xD;
             virus (HBV), or hepatitis C virus (HCV).&#xD;
&#xD;
         12. Current chronic daily treatment (continuous for &gt; 3 months) with systemic&#xD;
             corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone),&#xD;
             excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic&#xD;
             reaction or anaphylaxis in subjects who have known contrast allergies is allowed.&#xD;
&#xD;
         13. Known hypersensitivity to any component of the study medication(s).&#xD;
&#xD;
         14. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug&#xD;
             reaction with any of the study medications.&#xD;
&#xD;
         15. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including&#xD;
             ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone,&#xD;
             nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit&#xD;
             products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin,&#xD;
             rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study&#xD;
             day 1.&#xD;
&#xD;
         16. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8&#xD;
             inducer (rifampin) within 14 days before study day 1.&#xD;
&#xD;
         17. Participation in an investigational drug study or history of receiving any&#xD;
             investigational treatment within 14 days prior to screening for this study, except for&#xD;
             testosterone-lowering therapy in men with prostate cancer.&#xD;
&#xD;
         18. Assessed by the Investigator to be unable or unwilling to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
         19. Concurrent participation in any interventional clinical trial.&#xD;
&#xD;
         20. Pregnant and nursing women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 25, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

